Department of Pediatric Cardiology/Electrophysiology, Istanbul Mehmet Akif Ersoy Cardiovascular Research and Training Hospital, Saglik Bilimleri University, Istanbul, Turkey.
Department of Pediatric Cardiac Surgery, Istanbul Mehmet Akif Ersoy Cardiovascular Research and Training Hospital, Saglik Bilimleri University, Istanbul, Turkey.
Pacing Clin Electrophysiol. 2021 Jan;44(1):110-119. doi: 10.1111/pace.14126. Epub 2020 Dec 1.
Permanent pacemaker (PM) implantation is performed for various indications and by different techniques in children; however, many problems with lead performance are encountered during follow-up. This study aims to evaluate the possible effects of different lead types and implantation techniques on pacing at early and midterm in children with a permanent PM.
Pediatric patients who underwent permanent PM system implantation at our tertiary cardiac surgery center between January 1, 2010 and January 1, 2020 were evaluated retrospectively. Patients were categorized in the epicardial pacing lead (EP), transvenous pacing lead (TP), and transvenous bipolar lumenless (Select Secure [SS]) lead groups according to the lead implantation technique and lead type with the same manufacturer. Groups were evaluated statistically for demographic features, pacing type and indication for implantation, lead electrical performance, lead failure, complications, and outcome.
Over 10 years, 323 lead implantations were performed on 167 patients (96 males, median age 68 months [5 days-18 years]). Of 323 leads, 213 (66%) were EP, 64 (20%) were TP, and 46 (14%) were SS. Of the total, 136 of the leads were implanted in atria, and 187 were implanted in ventricles. Primary pacing indications were postoperative complete atrioventricular (AV) block (n = 95), congenital AV block (n = 71), sinus node dysfunction (n = 13), and acquired complete AV block (n = 1). Additional cardiac diseases were present in 115 patients (69%). No statistically significant difference was observed in gender, syndrome, or pacing indication (P > .05). Atrial and ventricular capture, threshold, sensing, and lead impedance measurements were not significantly different at the initial and follow-up periods (P > .05). The median follow-up duration was 3.3 years (6 months-10 years). Twenty lead failures were determined in 15 patients (EP: 14 lead failures in 10 patients; TP: two lead failures in two patients; and SS: four lead failures in three patients) during follow-up, and no statistically significant difference was found between groups (P = .466). The 5-year lead survival was 98% for TP, 95% for EP, and 90% for SS; the 10-year lead survival was 90% for TP, 70% for EP, and 70% for SS. There was no mortality related to chronic pacing or due to the procedure of implantation.
Despite improvements in technology, lead failure is still one of the most critical problems during these patients' follow-up. Early to midterm lead survival rates of all three lead types were satisfactory.
永久性心脏起搏器 (PM) 的植入有多种适应证,且采用不同的技术,但是在随访过程中会遇到许多导线性能问题。本研究旨在评估不同类型和植入技术的导线对儿童永久性 PM 早期和中期起搏的可能影响。
回顾性分析 2010 年 1 月 1 日至 2020 年 1 月 1 日期间在我们的三级心脏外科中心接受永久性 PM 系统植入的儿科患者。根据植入技术和相同制造商的导线类型,患者被分为心外膜起搏导线 (EP)、经静脉起搏导线 (TP) 和经静脉双极无腔 (SelectSecure [SS]) 导线组。对各组的人口统计学特征、起搏类型和植入适应证、导线电性能、导线故障、并发症和结果进行统计学评估。
在 10 年期间,对 167 例患者 (96 例男性,中位年龄 68 个月[5 天-18 岁]) 的 323 根导线进行了植入。323 根导线中,213 根 (66%) 为 EP,64 根 (20%) 为 TP,46 根 (14%) 为 SS。其中,136 根导线植入心房,187 根导线植入心室。主要起搏适应证为术后完全性房室 (AV) 阻滞 (n=95)、先天性 AV 阻滞 (n=71)、窦房结功能障碍 (n=13)和获得性完全性 AV 阻滞 (n=1)。115 例患者 (69%) 存在其他心脏疾病。性别、综合征或起搏适应证在各组间无统计学差异 (P>.05)。初始和随访时,心房和心室捕获、阈值、感知和导线阻抗测量均无显著差异 (P>.05)。中位随访时间为 3.3 年 (6 个月-10 年)。15 例患者中有 20 例导线出现故障 (EP:10 例患者中有 14 例导线故障;TP:2 例患者中有 2 例导线故障;SS:3 例患者中有 4 例导线故障),各组间无统计学差异 (P=.466)。TP 的 5 年导线存活率为 98%,EP 为 95%,SS 为 90%;TP 的 10 年导线存活率为 90%,EP 为 70%,SS 为 70%。没有与慢性起搏或植入过程相关的死亡。
尽管技术有所改进,但在这些患者的随访过程中,导线故障仍然是最关键的问题之一。三种导线类型的早期和中期导线存活率均令人满意。